Which enzyme produced from the secretor gene controls the production of H substance (Type I precursor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

L-fucosyltransferase (found in the saliva of secretors) is the Enzyme Produced from the Secretor Gene that Controls H Substance Production

The enzyme α-1,2-fucosyltransferase (L-fucosyltransferase) is the enzyme produced from the secretor gene (FUT2) that controls the production of H substance (Type I precursor). 1

Understanding the Secretor Gene and H Substance Production

The secretor gene (FUT2) encodes for a specific enzyme called α-1,2-fucosyltransferase, which is responsible for the production of H substance in secretory fluids like saliva. This enzyme catalyzes the transfer of L-fucose in an alpha-configuration to the 2-position of beta-D-galactopyranosyl units, creating the H antigen structure 1.

Key characteristics of this enzyme include:

  • It is specifically found in the saliva of secretor individuals
  • It is encoded by the FUT2 gene
  • It transfers L-fucose to create H substance, which serves as a precursor for ABH blood group substances in secretions

Biochemical Evidence Supporting L-fucosyltransferase

The biochemical evidence clearly demonstrates that the secretor gene (FUT2) is a structural gene encoding a specific fucosyltransferase:

  • Studies have shown that the secretor gene encodes α-1,2-fucosyltransferase, which has been purified from human milk and other secretions 2
  • This enzyme differs from the plasma-derived fucosyltransferase (encoded by the H gene) in several biochemical properties:
    • Different pH-activity profiles
    • Different thermal stability
    • Different substrate affinities for type 1 and type 2 chain acceptors 2

Molecular Genetics of Secretor Status

Secretor status is determined by the FUT2 gene, with non-secretors having various polymorphisms that result in inactive enzymes:

  • The most common polymorphism causing non-secretor status is the 428G→A mutation (found in 88.9% of non-secretors in one study) 3
  • Other polymorphisms like 739G→A and 839T→C result in almost inactive enzymes 3
  • These mutations prevent the production of functional α-1,2-fucosyltransferase, resulting in the absence of H substance in secretions

Clinical Significance

The secretor status determined by FUT2 and its encoded enzyme has important clinical implications:

  • Secretor status affects susceptibility to certain infections, as H substance and related fucosylated carbohydrates can serve as ligands for pathogens 3
  • In premature infants, non-secretor and low secretor status is associated with increased mortality, necrotizing enterocolitis, and gram-negative sepsis 4
  • The enzyme's activity in producing H substance has implications for blood group antigen expression in secretions

Distinguishing Features from Other Enzymes

The L-fucosyltransferase (α-1,2-fucosyltransferase) encoded by the secretor gene has distinct properties:

  • It has higher affinity for type 1 chain acceptors compared to type 2 chain acceptors, though the difference may be small in some tissues 5
  • It differs from the H gene-encoded plasma fucosyltransferase in divalent cation requirements and other biochemical properties 5
  • It is specifically expressed in secretory tissues rather than hematopoietic tissues

In conclusion, the enzyme produced from the secretor gene that controls the production of H substance (Type I precursor) is L-fucosyltransferase (α-1,2-fucosyltransferase), making option A the correct answer.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.